... Chemoprevention for Prostatic Intraepithelial Neoplasia Key Words Chemoprevention Prostate intraepithelial neoplasia Prostate carcinoma Finasteride Abstract Objectives: To evaluate the potential application of chemoprevention strate­ gies in prostatic intraepithelial neoplasia. Methods: Review of relevant litera­...

... of the 5α-reductase inhibitor finasteride and the antiandrogen flutamide was as effective as a luteinizing hormone-releasing hormone analog and flutamide in inhibiting the growth of the prostate. In a pilot trial, 10 potent patients with clinical stage C and D1 prostate cancer were given the combination...

...Roger S. Kirby; Justin Vale; Jenny Bryan; Kate Holmes; Judith Webb A group of 69 men with bladder outflow obstruction due to benign prostatic hyperplasia (BPH) were treated in a double-blind placebo-controlled study with finasteride (Proscar), a 5α-reductase inhibitor, 5 mg or 10 mg/day...

...H.O. Beisland; B. Binkowitz; E. Brekkan; P. Ekman; M. Kontturi; T. Lehtonen; P. Lundmo; F. Pappas; E. Round; D. Shapiro; E. Stoner; R. Swartz; E. Varenhorst The effects of finasteride, a potent 5a-reductase inhibitor, were assessed in patients with benign prostatic hyperplasia. Patients were...

...Evon Moore; Bruce Bracken; William Bremner; Jack Geller; Julianne Imperato-McGinley; John McConnel; Johnny Roy; Lisa Trevor; Darracotto Vaughan; Frances Pappas; Thomas Cook; Glenn Gormley; Elizabeth Stoner We assessed the long-term safety and efficacy of finasteride, an orally active 5α-reductase...

... were administered varying doses of the 5α-reductase inhibitor finasteride. Finasteride was found to be a potent inhibitor of both C(19) androgen and C(21) 5α-steroid metabolism affecting both hepatic and peripheral 5α-metabolism. The 5α-steroid metabolite profile was strikingly similar to that of MPHs...

...A. Vermeulen; V.A. Giagulli; P. De Schepper; A. Buntinx Finasteride is a potent competitive 5α-reductase inhibitor, active at a dose as low as 1 mg/day. After a single dose, the effects on 5α-reductase last as long as 7 days. Both hepatic and target tissue 5α-reductase are inhibited. Plasma...

... approximately 5 years ago and will achieve its primary endpoint in October 2004. At the start of the study, 18,882 men, aged over 55 years, and with normal digital rectal examination (DRE) and serum prostate-specific antigen (PSA) levels of ≤3.0 ng/ml were randomized to take finasteride (5 mg/day) or placebo (1...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. BHP LUTS Disease management Real life practice Quality of life α 1 -Adrenoceptor α 1 -Adrenoceptor antagonist Finasteride Surgery Lower urinary tract symptoms...

... such as alfuzosin and tamsulosin may reduce the risk of treatment failure with a comparable rate to finasteride. Although the different α 1 -AR antagonists are equivalent in efficacy they differ in tolerability with the subtype selective tamsulosin having the lowest risk for interference with blood pressure...

... to complications such as acute urinary retention or can ultimately require surgical treatment. In a placebo-controlled study finasteride was shown to reduce the incidence of acute urinary retention and the need for surgery in patients with LUTS suggestive of BPO. While α 1 -adrenoceptor antagonists are superior...

... of LUTS/BPH and assess the effectiveness of medical therapy between 1992 and 1998. Methods: 61,364 men with LUTS/BPH and without a record of prostatic cancer were identified on the database. 14,195 were treated with an α 1 -blocker or finasteride. Treatment failure was defined as prostatic surgery...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. α 1 -Adrenoceptor antagonists Finasteride Phytotherapy Lower urinary tract symptoms Benign prostatic obstruction...

... discussed. Methods: Information reviewed here comes mainly from published scientific articles and abstracts describing direct comparative trials among α 1 -adrenoceptor antagonists, finasteride, and/or phytotherapy. Results: Direct comparative trials demonstrated α 1 -adrenoceptor antagonists to be more...

... of finasteride therapy. Materials and Methods: Three thousand and forty men with moderate to severe symptoms of BPH and enlarged prostate glands by digital rectal examination were enrolled into the 4–year placebo–controlled PLESS trial and were evaluated for occurrences of AUR and BPH–related surgery. Men...

... by reduction of testosterone. Two isoenzymes of 5α–reductase have been discovered. Type 1 is present in most tissues of the body where 5α–reductase is expressed and is the dominant form in sebaceous glands. Type2 5α–reductase is the dominant isoenzyme in genital tissues, including the prostate. Finasteride...

... is more frequently used in Italy than in other European countries. Minimally invasive treatments remain a very small portion of interventions for the management of BPH in Italy. Fifty-five percent of patient days of treatment are α-blockers, 37% is finasteride. The share of α-blockers has dramatically...

.... A survey among urologists determined that for men with mild symptoms, watchful waiting was employed 77% of the time, α 1 -adrenoceptor antagonists 21% and finasteride 1%. For those with moderate symptoms and prostate volume ≤40 ml, α 1 -adrenoceptor antagonists are employed 88% of the time, finasteride 1...

... that for finasteride has remained flat. In 1998, α 1 -adrenoceptor antagonists had 64% market share and finasteride 36% from a total market of 53 million Euro. Conclusions: In the UK, challenges for the future management of symptomatic BPH will be the increased number of patients, further enhancement of efficient co...

... of clinical data. α 1 -Blockers and finasteride (for prostates >40 ml) are recommended medical treatment approaches. Transurethral resection of the prostate (TUR-P) is considered to be the standard surgical procedure. Preliminary data from the Herner LUTS-Study show, that approximately 30% of men aged 50...